Value-added medicines: how repurposed medicines bring value to patients and pharmacists

21 December 2017

The associations representing the European and British life science industry (AESGP, ABPI, BGMA, BIA, EBE, EFPIA, EUCOPE, EuropaBio, Medicines for Europe, PAGB, Vaccines Europe) have today launched a joint policy document on the potential impact of the United Kingdom’s exit from the European Union

14 December 2017

Today, organisations representing the life science industry in the EU […]

Europe’s life science industry urges the UK and EU27 to safeguard patients’ access to medicines with a clear transition period and a future cooperation agreement after Brexit

28 November 2017

The associations representing the European and British life science industry […]

Medicines for Europe calls for greater cooperation on value added medicines to improve patient-centric innovation

22 November 2017

The 1st Value Added Medicines conference organised by the Value […]

Medicines for Europe welcomes decision on EMA relocation to Amsterdam

21 November 2017

Medicines for Europe is very glad to see the Council […]

Manufacturing cost transparency could combat pricing criticism, says expert

2 November 2017

Medicines for Europe announces new President, launches Access to Medicines campaign

10 October 2017

The newly elected President of Medicines for Europe – Marc-Alexander Mahl – […]

Medicines for Europe to join the ISPOR Issue Panel on value added medicines

5 October 2017

Value added medicines represent a major opportunity to improve patients’ […]

Europe needs change to drive added value

15 September 2017

European report calms common concerns

15 September 2017